Understanding Measles: Symptoms, Prevention, and Control

Measles remains one of the most contagious infectious diseases known to humanity. Despite the availability of a safe and effective vaccine for over six decades, this viral illness continues to pose a significant public health challenge worldwide. In India, measles cases tend to peak during winter months, making awareness about its symptoms, prevention, and control especially important for healthcare professionals and communities alike. Understanding how this disease presents, spreads, and can be prevented is essential knowledge for nursing students and healthcare workers who serve as the first line of defense against outbreaks.

What is measles? 🔗

Measles, also known as rubeola, is an acute viral illness caused by the measles virus, a single-stranded RNA virus belonging to the genus Morbillivirus within the family Paramyxoviridae. This disease is highly contagious, with secondary attack rates exceeding 90% among susceptible individuals who have close contact with an infected person. Humans are the only known natural hosts for the measles virus, which means the disease cannot be transmitted from animals to humans.

The virus primarily targets the respiratory tract before spreading throughout the body. Once established, it causes systemic infection affecting multiple organ systems. Before the introduction of the measles vaccine in 1963, major epidemics occurred approximately every two to three years, causing an estimated 2.6 million deaths annually. Even today, the disease remains endemic in many regions, particularly in parts of Africa, the Middle East, and Asia, where vaccination coverage remains inadequate.

Signs and symptoms 🔗

Measles symptoms appear 7 to 14 days after contact with the virus. The illness follows a predictable clinical course that healthcare professionals should recognize early for prompt intervention and outbreak control.

Prodromal phase 🔗

The initial stage of measles is characterized by what clinicians often call the “three Cs” – cough, coryza (runny nose), and conjunctivitis (red, watery eyes). During this phase, patients also experience fever that may climb as high as 104°F (40°C). This prodromal period typically lasts 2-4 days before the characteristic rash appears. Many patients also develop malaise and loss of appetite during this time.

Koplik’s spots: the pathognomonic sign 🔗

One of the most diagnostically significant features of measles is the appearance of Koplik’s spots. These small, irregular spots appear on the buccal mucosa, typically opposite the upper molars, and are described as bright red spots with white or bluish-white centers resembling grains of sand. First described by Dr. Henry Koplik of New York in 1896, these spots are considered pathognomonic, meaning their presence definitively indicates measles infection.

Koplik’s spots usually appear 1-2 days before the skin rash develops and can be identified in 60-70% of measles cases. Their early identification is crucial because it allows healthcare providers to diagnose measles before the patient reaches maximum infectivity, enabling prompt isolation measures to prevent further transmission.

The characteristic rash 🔗

The measles rash typically appears 3-5 days after the first symptoms begin. It starts as flat red spots on the face at the hairline and behind the ears, then spreads downward to the neck, trunk, arms, and legs over the next 2-3 days. Small raised bumps may develop on top of the flat red spots. As the rash spreads from head to feet, the spots often merge together. When the rash appears, the patient’s fever may spike significantly. The rash usually persists for 5-6 days before fading in the same order it appeared.

How measles spreads 🔗

Measles is transmitted primarily through airborne respiratory droplets produced when an infected person coughs, sneezes, or even talks. The virus can also spread through direct contact with nasal or throat secretions of infected individuals. What makes measles extraordinarily contagious is the virus’s ability to remain active and infectious in the air or on contaminated surfaces for up to two hours after an infected person has left the area.

The infectivity of measles is remarkably high. If an unvaccinated person is exposed to someone with measles, approximately 90% of susceptible contacts will become infected. An infected individual can spread the disease from four days before the rash appears until four days after the rash erupts. This means transmission often occurs before the infected person even knows they have measles, making outbreak control particularly challenging.

Complications of measles 🔗

While many patients recover from measles without long-term consequences, complications occur in approximately 30% of cases and can be severe or even fatal. The risk of complications is highest in children under five years, adults over 20 years, pregnant women, and immunocompromised individuals.

Respiratory complications 🔗

Bronchopneumonia represents one of the most common and serious complications of measles. Pneumonia occurs in up to 1 in 20 children with measles and is the most frequent cause of measles-related deaths in young children. The infection may be caused directly by the measles virus or by secondary bacterial pathogens. Other respiratory complications include bronchitis, laryngitis, and croup (laryngotracheobronchitis).

Gastrointestinal complications 🔗

Diarrhea is another frequent complication, occurring in approximately 8% of measles cases. Severe diarrhea combined with reduced fluid intake can lead to dangerous dehydration, particularly in young children. In malnourished children, this complication can be life-threatening.

Neurological complications 🔗

Encephalitis (inflammation of the brain) develops in approximately 1 in 1,000 children who contract measles. This serious complication can lead to convulsions, permanent brain damage, deafness, or intellectual disability. A rare but fatal late complication called subacute sclerosing panencephalitis (SSPE) can develop 7-10 years after measles infection, causing progressive neurological deterioration.

Impact on malnourished children 🔗

Complications are more likely in children who are malnourished, especially those with vitamin A deficiency or weakened immune systems from HIV or other diseases. Malnutrition contributes to measles deaths in approximately 45% of fatal cases. The relationship between measles and malnutrition is bidirectional: measles is more severe in malnourished children, and the infection itself can lead to or worsen malnutrition through reduced food intake, diarrhea, and metabolic stress.

Malnourished children experience prolonged viral shedding, depressed cell-mediated immunity, and increased susceptibility to secondary infections. This creates a dangerous cycle where measles further compromises the immune system, making children vulnerable to other opportunistic infections that can prove fatal.

Prevention through vaccination 🔗

Vaccination remains the single most effective strategy for preventing measles. The measles vaccine provides approximately 95% protection when administered at the recommended age. The vaccine, which uses a live attenuated strain of the measles virus, has been in use for over 60 years and has an excellent safety profile supported by extensive research involving millions of children.

Vaccination schedule 🔗

In countries where measles is common, the first dose is recommended at 9 months of age, while in other countries, it is given at 12-15 months. A second dose should be administered at 15-18 months or later during childhood. The vaccine is commonly given as the MMR (measles, mumps, rubella) combination vaccine. Two doses of the MMR vaccine provide about 97% effectiveness in preventing measles for life.

Herd immunity 🔗

Because measles is so highly contagious, achieving and maintaining high vaccination coverage is essential for community protection. Experts estimate that approximately 95% of a population must be immune to prevent measles transmission and protect vulnerable individuals who cannot be vaccinated, such as infants and immunocompromised persons.

Treatment and management 🔗

There is no specific antiviral treatment for measles. Medical care focuses on supportive management, symptom relief, and prevention of complications. Patients should maintain adequate hydration, especially if experiencing diarrhea or vomiting. Fever-reducing medications like paracetamol can help manage discomfort.

Vitamin A supplementation 🔗

All children with measles should receive two doses of vitamin A supplements, given 24 hours apart. This supplementation restores vitamin A levels that become depleted during measles infection, even in well-nourished children. Vitamin A can help prevent eye damage and blindness and has been shown to reduce measles-related mortality.

Management of complications 🔗

Secondary bacterial infections such as pneumonia, ear infections, and eye infections may require antibiotic treatment. Patients should be monitored closely for signs of complications, particularly if fever persists beyond two days after rash onset. Hospitalization may be necessary for severe cases, especially in immunocompromised patients or those with respiratory distress.

Role of healthcare workers in measles control 🔗

Nurses and other healthcare professionals play a critical role in measles prevention and control. Early recognition of Koplik’s spots and other symptoms enables prompt diagnosis before the rash appears, allowing for immediate isolation and notification of public health authorities. Healthcare workers should maintain high vaccination coverage among staff and educate communities about the importance of timely immunization.

Infection control measures in healthcare settings include placing suspected measles patients in airborne isolation with appropriate respiratory precautions. Contact tracing and post-exposure prophylaxis for susceptible individuals exposed to confirmed cases are essential components of outbreak response.

What do you think? Given the high contagiousness of measles and its potential for serious complications in vulnerable populations, how can healthcare professionals better promote vaccine acceptance in communities where hesitancy exists? What strategies might be most effective in reaching children who remain unvaccinated?

References

1. https://www.ncbi.nlm.nih.gov/books/NBK448068/
2. https://www.who.int/news-room/fact-sheets/detail/measles
3. https://www.cdc.gov/measles/signs-symptoms/index.html
4. https://www.ncbi.nlm.nih.gov/books/NBK549793/
5. https://www.mayoclinic.org/diseases-conditions/measles/symptoms-causes/syc-20374857
6. https://www.cdc.gov/measles/causes/index.html
7. https://www.msdmanuals.com/professional/pediatrics/common-viral-infections-in-infants-and-children/measles
8. https://www.nejm.org/doi/full/10.1056/NEJMra2504516
9. https://ourworldindata.org/measles-vaccine-effectiveness-safety